Dr. Luke Benjamin Fletcher, MD

Dr. Fletcher practices at Willamette Valley Cancer Institute and Research Center in Eugene, Oregon.

Dr. Fletcher's NPI, 1770979098, was assigned on April 14, 2015. Dr. Fletcher graduated from Keck School of Medicine of USC in 2015. Dr. Fletcher's Oregon license number on file is MD186947.

Dr. Fletcher's primary practice is Willamette Valley Cancer Institute and Research Center, at 520 Country Club Pkwy, Eugene, OR 97401 in Lane County. The practice phone is (541) 683-5001.

Dr. Fletcher's primary practice is Willamette Valley Cancer Institute and Research Center in Eugene, Oregon. Dr. Fletcher is also affiliated with PeaceHealth Sacred Heart Medical Center RiverBend. The medical group on file is Willamette Valley Cancer Institute & Research Center. Dmand AI also links Dr. Fletcher to 4 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Fletcher practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Fletcher's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Fletcher is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Fletcher's licenses on file in 2 states: Oregon and Texas.

Dmand AI lists breast cancer, chronic anemia, colorectal cancer, lung cancer, lymphoma, multiple myeloma, prostate cancer and purpura and thrombocytopenia among the conditions Dr. Fletcher treats.

CMS data shows 66,029 Medicare services from Dr. Fletcher across 58 procedure codes in 2024, for 555 Medicare patients. Medicare paid $847,318 for them.

CMS counts 555 Medicare patients who saw Dr. Fletcher in 2024. The largest group is 65 to 74, with 270 patients. 64% of them have high blood pressure, and 63% have high cholesterol. 12% are also on Medicaid. Their average risk score is 1.96, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Fletcher's median patient age at 71, with 55% women.

In 2024, Dr. Fletcher wrote 1,686 Medicare Part D claims for 261 patients. 83% of them were for generic drugs. CMS names the drug for 1,289 of them, across 39 drugs with 11 or more claims each, at $2,974,838 in total drug cost. In 2023, CMS named 611 claims across 21 drugs.

Dr. Fletcher accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Fletcher as offering telehealth.

Dmand AI links 14 papers to Dr. Fletcher, published from 2012 to 2025. 2012 was the busiest year, with 4. The most frequent topics are Antineoplastic Agents, Apoptosis and Cell Survival. Dr. Fletcher has published most often in Cancer Res. Dr. Fletcher's most frequent co-authors are Brian Jay Druker, MD, Sunil Babu, MD and Rupali Roy Bhave, MD.

Dmand AI links Dr. Fletcher to 5 clinical trials, 2 of them phase 3 studies. 4 are still active or recruiting. Conditions studied include Leukemia, Myeloid, Acute, Myelodysplastic Syndromes and Philadelphia Chromosome.

CMS Open Payments shows 70 general payments to Dr. Fletcher from 25 drug and device companies from 2017 to 2025. Consulting fees make up the largest share, 78% of the total. CTI BioPharma Corp. paid the most, $6,091. It also lists 3 research payments totaling $2,248 from 2024 to 2025.

Dr. Fletcher graduated from Keck School of Medicine of USC in 2015. Dr. Fletcher is a member of ASCO and ASH.

Dr. Fletcher is in network with 15 carriers, including Aetna, United Healthcare and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.